Infectious Disease Clinical Development Expertise

Infectious diseases and other emerging health challenges are a threat
everywhere – not just in low-income and non-western countries. Time is of the essence when it comes to infectious disease treatments, especially as antibiotics become less effective and as new viral strains appear.

Veristat is committed to helping clients advance their life-saving treatments and prevention of life-threatening infectious diseases.   Veristat teams have conducted more than 160 Infectious Disease programs for drugs, biologics and vaccines.

Experience Battling Infectious Diseases

Whether you are aiming to prevent or combat a viral, bacterial, fungal or parasitic infection, Veristat can help make the difference for your study’s success. Our teams understand the nuances and difficulties involved with treating infectious diseases, have the experience to perform vaccine trials, and are adept with rapid response to global pandemics that arise.
infectious_disease_stats

Explore Our Recent Infectious Disease Experience

 

infectious_disease_experience_table

 

Learn More with These Resources

Fact Sheet

Data-Driven Strategies to Advance Development and Approval ...

This fact sheet provides an overview of Veristat's data-drive approach to supporting the development, clinical execution, and regulatory approval of rare and ultra-rare ...

DOWNLOAD

Case Study

Flexibility Drives Progress in Rare Disease Gene Therapy ...

In this case study, learn how Veristat adapted clinical operations, site strategy, and reporting in real time to keep a rare disease gene therapy trial moving forward despite ...

DOWNLOAD

Case Study

Supporting Global Approval of a First-in-ClassGene Therapy ...

Learn how Veristat coordinated clinical operations to support U.S. and EU approval of a rare disease gene therapy.

DOWNLOAD
Request A Proposal
  • Privacy Policy

  • ©2023 Veristat, LLC. All rights reserved. Veristat is a trademark of Veristat, LLC. All other trademarks are the property of their respective owners.